65,437 trials
Gingivitis
Primary: Whole Mouth Mean Bleeding Index (BI) at Week 3 — 0.14; 0.20 score on a scale — p=<0.0001
Schizophrenia
Primary: Adverse Events and Adverse Drug Reactions, Etc. — 82; 92; 174; 60 Participants
Executive Function
Primary: Number of Remembered Items — 1.863; 1.754; 1.796; 1.797 number of remembered items — p=0.263
Urinary Retention
Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants
Alzheimer's Disease
Primary: Number of Participants With Vital Signs Abnormalities of Potential Clinical Concern — 0; 0; 0; 0 participants
Chronic Plaque Psoriasis
Primary: Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 — 0; 46.2; 67.4; 75.0…
Dry Eye Disease
Primary: Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears — 0.047; 0.049; 0.031; 0.032 (µl/cm2/min)
Cholera (Disorder)
Primary: Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae — 99.4; 0 percentage of participants
Drug-Related Side Effects and Adverse Reactions · Adverse Drug Events
Primary: Medication Discrepancies — 6.4; 4.4 Medication Discrepancies
Diabetes Mellitus Type 2
Primary: Absolute Change in HbA1c — 7.872; 7.939; 8.006; 7.998 Percentage
Peritoneal Dialysis
Primary: Intra-Abdominal Pressure (IAP) — -0.5; -0.2; -1.2 mm Hg
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Best Overall Response and Objective Response Rate Following Treatment With CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or…
Healthy Volunteers
Primary: Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) — 2; 5; 0; 4 Participants
Cardiac Diagnostic Procedure · Cardiac Interventional Procedure · Femoral Access Site Closure
Primary: Assessment of Venous Thrombosis — 0; 0 Participants